Enasidenib: A Promising Option for IDH2-Mutated Acute Myeloid Leukemia?

The authors explored the evidence supporting the safety and side effect profile of enasidenib, FDA-approved in August 2017 for relapsed/refractory AML.

Source: CancerNetwork - May 6, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news